FLT3 inhibitors
Use of FLT3 inhibitors in acute myeloid leukemia remission induction or salvage therapy: systematic review and meta-analysis
18
Clinical use of FLT3 inhibitors in acute myeloid leukemia
12
FLT3 inhibitors: clinical potential in acute myeloid leukemia
9
Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors
7
FLT3 inhibitors in acute myeloid leukemia
11
Early changes in rpS6 phosphorylation and BH3 profiling predict response to chemotherapy in AML cells
17
T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3 -ITD mutated acute myeloid leukemia
16
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors
14
Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells
15
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia
17
FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia
17
Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification
12
An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia
11
SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells
6
Generation and characterization of a highly effective protein substrate for analysis of FLT3 activity
5
Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
6
CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia
18
Abundance of Flt3 and its ligand in astrocytic tumors
7
Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
12
Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia
12